TREM2 and multiple sclerosis: Kazuya Takahashi et al. reported that intravenous application of TREM2-transduced bone marrow-derived myeloid precursor cells after multiple sclerosis in mice increased lysosomal and phagocytic activity, cleared degenerated myelin, and reduced the inflammatory response at spinal cord lesions [22].